|
|
|
|
|
|
|
| Draper Technology Innovation Fund |
| |
Application Deadlines: January 25, 2010; April 26, 2010
The Draper Technology Innovation Fund (TIF) provides a mechanism to support the additional research often necessary to bring new concepts and inventions to the patent and licensing stage. The program goal is the eventual introduction of new products and processes into the market place for the public good. Funds can be used to support efforts to enhance the scope or patentability of inventions and assist with their potential licensing to the commercial sector. Examples of research activities include prototype development, preparation of samples for evaluation, and application testing.
Applicants must be University of Wisconsin-Madison faculty members or
academic staff. A formal University invention disclosure must have been
accepted by the Wisconsin Alumni Research Foundation (WARF).
Changes to 2009-10 Competition
*Fringe benefits should be included in the budget and will be charged
to the grant.
*Awards cannot exceed $50,000 |
|
| Lead Discovery Initiative |
| |
Application deadlines: Applications will be accepted on
a continuous basis and will be reviewed
In conjunction with the Keck-UW Carbone Cancer Center Small Molecule Screening
Facility (SMSF), WARF is launching a new initiative for assay development and
small molecule screening. The Lead Discovery Initiative addresses the development
and application of high-throughput screening assays to the identification of
small molecules that play a role in pathway modulation and have potential for
future commercial development.
Researchers who have characterized putative regulatory elements or drug targets
in any therapeutic indication are encouraged to apply. The program is also open
to researchers who have already begun to conduct small molecule screens of putative
drug targets through initial work at the SMSF, but lack the funds to develop
structure activity relationships (SAR) for lead candidates.
Work under the Lead Discovery Initiative will be carried out at the SMSF, with
WARF funding administered directly to SMSF. The program is designed to assist
in assay development, screening the existing compound library, and ultimately,
obtaining expanded compound libraries from commercial sources to further develop
SAR. Applications will be evaluated on a monthly basis by a core team comprising
representatives from the School of Pharmacy, the SMSF and WARF.
All UW researchers are eligible to apply in conjunction with a principal investigator.
Applicants must have submitted a WARF Invention
Disclosure Report (IDR) prior to, or may do so at the same time as their LDI
application. Additional details regarding the initiative can be found in
the Request
for Applications.
Questions about the initiatives should be directed to:
Laura M. Heisler, PhD
Manager, WARF Strategic Technology Enhancement Program
608-261-1022
For questions concerning the UWCCC SMSF or specific SMSF services, contact
Noël Peters MS
Screen Facility Director
608.265.8687 |
|
| Physician Scientist Training in Cancer Medicine
(T32) |
| |
Application deadlines: January 1, 2010
We are currently accepting applications for the Physician Scientist Training in Cancer Medicine
(T32) Program for positions beginning in July 2010.
This training program provides a 1-2 year
(July through June) period of support to train physician scientists in laboratory and/or
translational research specifically related to cancer, and is open to postdoctoral (MD) trainees. In
addition to the research conducted, it is expected that trainees in this program will identify and
complete a course curriculum to include biostatistical methods, population health, and the
responsible conduct of scientific research. Trainees and mentors will also be expected to attend
an annual presentation of research by the trainees.
Applicants will need to submit an application form, summary of
proposed research and curriculum, two names for possible letters of reference, and curriculum
vitae to Marilyn Larson by January 1, 2010. Mentors should also submit a brief letter,
including a description of the laboratory training environment and the proposed research project,
and an NIH biosketch to Marilyn Larson also by January 1.
For more information contact Marilyn Larson.
T32 Announcement
T32 Information
T32 Application Form
|
|
|
|
|
|